Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | P4HB | P07237 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19437370 | 1.00 | NPC1 (0.48) | NPC1MEN1KMT2AP4HBPOLB | |
| SCHEMBL16742176 | 0.83 | NOTUM (0.47) | MEN1KMT2AP4HBMAPTALDH1A1 | |
| SCHEMBL16744293 | 0.83 | NOTUM (0.47) | MEN1KMT2AP4HBMAPTALDH1A1 | |
| SCHEMBL31683121 | 0.83 | NPC1 (0.48) | NPC1MEN1KMT2AP4HBPOLB | |
| SCHEMBL19437403 | 0.81 | NPC1 (0.53) | NPC1MEN1KMT2APOLBRAB9A | |
| SCHEMBL19437402 | 0.81 | NPC1 (0.53) | NPC1MEN1KMT2APOLBRAB9A | |
| SCHEMBL5987282 | 0.79 | KDM4E (0.52) | MEN1KMT2AP4HBMAPTALDH1A1 | |
| SCHEMBL382703 | 0.78 | SMPD1 (0.59) | NPC1RAB9AMAPTALDH1A1LMNA | |
| SCHEMBL19456270 | 0.77 | NPC1 (0.44) | NPC1MEN1KMT2APOLBRAB9A | |
| SCHEMBL19437312 | 0.77 | NPC1 (0.57) | NPC1MEN1KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884083-B | Benzo [ B ] furans as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| EP-3440075-B1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-05-23 | — | — | US | disclosed |
| EP-3440075-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017174620-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | BRD4, BRD3, BRD2 | NPC1 2726/4885MEN1 2810/4885KMT2A 502/4885 |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | NPC1 2726/4885MEN1 2810/4885KMT2A 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.